{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:55:15Z","timestamp":1792184115437,"version":"4.4.0"},"reference-count":95,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001254","name":"Ipsen Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>To review direct comparative studies of the gonadotrophin\u2010releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) \u2018prostate cancer\u2019 and \u2018triptorelin\u2019 and \u2018leuprorelin\u2019, (ii) \u2018prostate cancer\u2019 and \u2018triptorelin\u2019 and \u2018goserelin\u2019, and (iii) \u2018prostate cancer\u2019 and \u2018goserelin\u2019 and \u2018leuprorelin\u2019, without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety\/tolerability, and five on the convenience of administration\/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate\u2010specific antigen. Some studies suggest differences in short\u2010 or long\u2010term testosterone control, the rate of injection site adverse events, and patient\/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.<\/jats:p>","DOI":"10.1111\/bju.14168","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T13:47:03Z","timestamp":1518529623000},"page":"371-383","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Are all gonadotrophin\u2010releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review"],"prefix":"10.1111","volume":"122","author":[{"given":"Eva M.","family":"Bolton","sequence":"first","affiliation":[{"name":"Department of Urology St James's Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Urology St James's Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S12700"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07590.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(71)90766-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112673"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-111-1-152"},{"key":"e_1_2_8_8_1","first-page":"173","article-title":"Current concept for improving treatment of prostate cancer based on combination of LH\u2010RH agonists with other agents","volume":"243","author":"Schally AV","year":"1987","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_8_9_1","unstructured":"MillarRP TroskieBE FlanaganCA.Comparative receptor binding affinity and inositol phosphate production potency of D\u2010Leu6and D\u2010Trp6 GnRH agonists on COS\u2010l cells transfected with the human GnRH receptor.XIII International Congress of Comparative Endocrinology1997; Yokohama Japan; 16\u201321 November 1997."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500716"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.t01-1-00592.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.195560"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.5.4.605"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253061"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.1990.tb00262.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(99)00371-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000056540"},{"key":"e_1_2_8_18_1","first-page":"252","article-title":"Pharmacodynamic equivalence of a decapeptyl 3\u2010month SR formulation with the 28\u2010day SR formulation in patients with advanced prostate cancer","volume":"62","author":"Teillac P","year":"2004","journal-title":"Horm Res"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475122"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215577329"},{"key":"e_1_2_8_21_1","unstructured":"AstraZeneca UK Ltd.Zoladex 3.6 mg. Summary of Product Characteristics 2017. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/1543. Accessed February 2018"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00161-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80087-X"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319690-000000000-00000"},{"key":"e_1_2_8_25_1","unstructured":"Ipsen Ltd.Decapeptyl SR. 3 mg. Summary of Product Characteristics 2016. Available at:https:\/\/www.surgery-express.co.uk\/files\/ww\/V068-Decapeptyl-SR-3mg.pdf. Accessed February 2018"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039010-00003"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000023241"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64625-3"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960230705"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_8_31_1","unstructured":"Oxford Centre for Evidence\u2010Based Medicine (OCEBM).OCEBM Levels of Evidence Working Group \u2013 \u2018The Oxford Levels of Evidence\u2019 August 2017. Available at:http:\/\/www.cebm.net\/index.aspx?o=5653. Accessed February 2018"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-012-0134-z"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988314552468"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07374.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000480796","article-title":"A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer","volume":"32","author":"Kuhn JM","year":"1997","journal-title":"Eur Urol"},{"key":"e_1_2_8_36_1","first-page":"984","article-title":"[Tolerance and clinical and biological responses during the first 6 months of treatment with 1\u2010month sustained release LHRH agonists leuprolerin and triptorelin in patients with metastatic prostate cancer]","volume":"7","author":"Abbou CC","year":"1997","journal-title":"Prog Urol"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04308.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.30"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11190.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/01485010601166870"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00145-9"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.540"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.09.009"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.7257\/1053-816X.2013.33.5.236"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2005.02.001"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500778"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500625"},{"key":"e_1_2_8_48_1","unstructured":"Takeda.Prostap 11.25 mg. Summary of Product Characteristics 2016. Available at:http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con120444.pdf. Accessed February 2018"},{"key":"e_1_2_8_49_1","unstructured":"Takeda.Prostap 3.75 mg. Summary of Product Characteristics 2016. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/4650\/smpc. Accessed February 2018"},{"key":"e_1_2_8_50_1","unstructured":"AstraZeneca UK Ltd.Zoladex LA. 10.8 mg. Summary of Product Characteristics 2017. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/1567. Accessed February 2018"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S44855"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000056547"},{"key":"e_1_2_8_53_1","first-page":"1168","article-title":"Efficacy and safety of leuprorelin acetate 6\u2010month depot in prostate cancer patients: a Phase III, randomized, open\u2010label, parallel\u2010group, comparative study in Japan","volume":"45","author":"Suzuki K","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62383-8"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.158"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0466-7"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13455"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04552.x"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S111475"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13482"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4303"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.05.072"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.129"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1013"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2008.n.008"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810095"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0481-1"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06609.x"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12142"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.09.010"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11107.x"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356272"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215574480"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/978194"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217712379"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.07.033"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.4578"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3752"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2009.01456.x"},{"key":"e_1_2_8_80_1","first-page":"947040","article-title":"Foreign body granulomas induced by intramuscular leuprorelin acetate injection for prostate cancer: clinical mimics of soft tissue sarcoma","volume":"2015","author":"Thway K","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"e_1_2_8_81_1","first-page":"106","article-title":"A case of foreign body granuloma induced by subcutaneous injection of leuprorelin acetate horizontal line clinical analysis for 335 cases in our hospital horizontal line","volume":"39","author":"Kawai M","year":"2014","journal-title":"Tokai J Exp Clin Med"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2007.48.3.421"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.74.306"},{"key":"e_1_2_8_84_1","first-page":"301","article-title":"Injection\u2010site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer","volume":"98","author":"Shiota M","year":"2007","journal-title":"Fukuoka Igaku Zasshi"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2015.05.005"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.7.2267"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-254"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2003.00705.x"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.005"},{"key":"e_1_2_8_90_1","first-page":"63","article-title":"Androgen deprivation therapy for prostate cancer: long\u2010term safety and patient outcomes","volume":"5","author":"Ahmadi H","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"e_1_2_8_91_1","first-page":"275","article-title":"Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment","volume":"63","author":"Herranz AF","year":"2010","journal-title":"Arch Esp Urol"},{"key":"e_1_2_8_92_1","unstructured":"PharmaA.Eligard 22.5 mg Summary of Product Characteristics 2017. Available at:http:\/\/www.medicines.ie\/medicine\/11073\/SPC\/Eligard+22.5mg\/. Accessed February 2018"},{"key":"e_1_2_8_93_1","unstructured":"Ipsen Ltd.Decapeptyl SR. 11.25 mg. Summary of Product Characteristics 2016. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/30\/smpc. Accessed February 2018"},{"key":"e_1_2_8_94_1","unstructured":"Ipsen Ltd.Decapeptyl SR. 22.5 mg. Summary of Product Characteristics 2017. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/5906\/smpc. Accessed February 2018"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.71"},{"key":"e_1_2_8_96_1","first-page":"749","article-title":"[Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?]","volume":"34","author":"Vilar\u2010Gonzalez S","year":"2010","journal-title":"Actas Urol Esp"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.14168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.14168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:26:03Z","timestamp":1761740763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.14168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/bju.14168"],"URL":"https:\/\/doi.org\/10.1111\/bju.14168","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"2018-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}